Blog
RSS FeedPosted by Michael Wonder on 16 Jun 2016
Sacubitril with valsartan in heart failure: differentiated value added
16 June 2016 - Addendum results in a revised benefit assessment for patients with type 2 diabetes mellitus. ...
Posted by Michael Wonder on 16 Jun 2016
NICE publishes appraisal consultation for cobimetinib hemifumarate (Cotellic) for patients with malignant melanoma
16 June 2016 - NICE has published an appraisal consultation for Roche's cobimetinib hemifumarate (Cotellic). ...
Posted by Michael Wonder on 16 Jun 2016
Updated NICE quality standard identifies areas for breast cancer improvement
15 June 2016 - NICE’s latest quality standard published today says people who have been diagnosed with a type of early ...
Posted by Michael Wonder on 16 Jun 2016
Roche’s Gazyvaro approved in Europe in combination with bendamustine for people with previously treated follicular lymphoma
16 June 2016 - This is the second approval in Europe for Gazyvaro based on a positive phase III study. ...
Posted by Michael Wonder on 16 Jun 2016
Shire and Kamada announce FDA approval of expanded label for self-infusion of Glassia for the treatment of emphysema due to severe AAT deficiency
15 June 2016 - Glassia is the only FDA approved alfa-1 antitrypsin (human) augmentation treatment that patients can self-infuse at home. ...
Posted by Michael Wonder on 15 Jun 2016
Osimertinib mesylate in lung cancer: no assigned additional benefits
15 June 2016 - No direct comparative studies / effects in historical comparisons too small for statements for additional benefits. ...
Posted by Michael Wonder on 15 Jun 2016
Orfadin 20 mg capsules approved in the US
15 June 2016 - Swedish Orphan Biovitrum AB (Sobi) announced today that the FDA has approved a higher strength 20 mg ...
Posted by Michael Wonder on 15 Jun 2016
Health Canada approves Inflectra (biosimilar Infliximab) for three additional indications: Crohn's disease, fistulising Crohn's disease and ulcerative colitis
14 June 2016 - Hospira today announced that Inflectra (biosimilar infliximab) has been approved by Health Canada for three additional indications, ...
Posted by Michael Wonder on 14 Jun 2016
FDA approves AspireAssist obesity device
14 June 2016 - The U.S. FDA today approved a new obesity treatment device that uses a surgically-placed tube to drain ...
Posted by Michael Wonder on 14 Jun 2016
NICE recommends laser device to help thousands of men with an enlarged prostate
14 June 2016 - Thousands of men could benefit from laser treatment for an enlarged prostate as recommended in new guidance ...
Posted by Michael Wonder on 13 Jun 2016
Prostate cancer drug decision 'grossly unfair'
13 June 2016 - A charity has said it is "grossly unfair" that men with advanced prostate cancer in Scotland will ...
Posted by Michael Wonder on 13 Jun 2016
Shire receives FDA breakthrough therapy designation for SHP621 and SHP625, investigational products for rare gastro-intestinal conditions
13 June 2016 - Shire today announced that the U.S. FDA has granted breakthrough therapy designation for two investigational products for ...
Posted by Michael Wonder on 13 Jun 2016
SMC - June 2016 decisions
13 June 2016 - Treatments for Parkinson’s disease, advanced leukaemia and asthma among four new medicines accepted for routine use in ...
Posted by Michael Wonder on 10 Jun 2016
FDA approves vaccine to prevent cholera for travelers
10 June 2016 - The U.S. FDA today approved Vaxchora, a vaccine for the prevention of cholera caused by serogroup O1 ...
Posted by Michael Wonder on 09 Jun 2016
NICE’s Eylea guideline ‘out of touch with clinical practice’
9 June 2016 - Bayer says it is disappointed that NICE is supporting NHS use of anti-VEGF therapy Eylea to treat ...